Clinical Resource: Toxicity Management Guide for Erdafitinib and Enfortumab Vedotin in Treatment of Urothelial Carcinoma

Download this PDF clinical resource on toxicity management to help optimize the care of your patients with progressive urothelial carcinoma receiving erdafitinib or enfortumab vedotin.
Kinjal Patel, PharmD, BCOP
Susan Roethke, CRNP, MSN, AOCN, ANP-BC
Format: Adobe Acrobat (.pdf)
File Size: 99 KB
Released: November 5, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Astellas and Seattle Genetics, Inc.

Related Content

Slides from Arjun Balar, MD on the role of biomarkers in managing urothelial cancer, from Clinical Care Options (CCO)

person default Arjun Balar, MD Released: April 21, 2021

Get expert insight from Arjun Balar, MD on the role of biomarkers in managing urothelial or bladder cancer, from Clinical Care Options (CCO)

person default Arjun Balar, MD person default Kaitlynn Francese, MSN, RN, OCN Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: April 21, 2021 Expired: April 20, 2022

Expert slides on biologic principles, indications, and clinical biomarkers for immune checkpoint inhibitors, from Clinical Care Options (CCO)

Sandip P. Patel, MD Released: April 16, 2021

Expert slides on multidisciplinary management of immune-related adverse events associated with checkpoint inhibitors, from Clinical Care Options (CCO)

Marianne Davies, DNP, CNS, ACNP-BC, AOCNP Released: April 16, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue